Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its name to ImmunityBio, Inc. in June 2019. The company was incorporated in 2014 and is based in El Segundo, California. ImmunityBio, Inc. operates as a subsidiary of NantWorks, LLC.
Website: immunitybio.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. Gross margin is high, +100.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 25% of quarters (showing a gain of -$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -28.4% (LTM)

Entry Point: Share price is 127.9% higher than minimum and 68.7% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: IBRX
Share price, USD:  (-5.0%)2.86
year average price 3.40  


year start price 5.61 2024-07-27

max close price 6.18 2024-10-29

min close price 1.89 2025-05-07

current price 2.86 2025-07-26
Common stocks: 397 957 006

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 1 138
Net Debt ($m): 599
EV (Enterprise Value): 1 737
Price to Book: -1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-25businesswire.com

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

2025-07-21seekingalpha.com

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

2025-07-07businesswire.com

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

2025-05-12zacks.com

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

2025-05-05seekingalpha.com

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

2025-05-05businesswire.com

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

2025-04-29seekingalpha.com

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

2025-04-07prnewswire.com

Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

2025-04-07businesswire.com

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

2025-04-03seekingalpha.com

ImmunityBio: Taking Care Of Business
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IBRX IBRX IBRX IBRX IBRX IBRX IBRX IBRX IBRX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-12 2024-08-12 2024-05-09 2024-03-19 2023-11-09 2023-08-08 2023-05-11 2023-03-01 2022-11-09
acceptedDate 2024-11-12 07:30:57 2024-08-12 08:03:23 2024-05-09 17:00:00 2024-03-19 16:31:53 2023-11-08 21:28:46 2023-08-08 16:15:53 2023-05-11 06:47:06 2023-03-01 17:18:49 2022-11-08 20:52:01
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 6M 1M 40 000 139 000 82 000 41 000 360 000 73 000 118 000
costOfRevenue 152 000 0 5M 5M 5M 6M 0 0 0
grossProfit 6M 1M -5M -4M -5M -6M 360 000 73 000 118 000
grossProfitRatio 0.975 1 -112.875 -31.835 -54.915 -153.098 1 1 1
researchAndDevelopmentExpenses 50M 51M 53M 51M 48M 53M 79M 58M 72M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 36M 49M 38M 29M 32M 32M 33M 26M 19M
otherExpenses 0 0 -20 000 -37M 6M -7M -1M -923 000 0
operatingExpenses 86M 100M 91M 80M 80M 85M 112M 84M 91M
costAndExpenses 86M 100M 95M 85M 80M 85M 112M 84M 91M
interestIncome 638 000 833 000 160 000 2M 35 000 592 000 284 000 515 000 253 000
interestExpense 40M 39M 37M 32M -35M 32M 30M 29M 17M
depreciationAndAmortization 4M 4M 5M 5M 5M 5M 2M 2M 293 000
ebitda -80M -91M -91M -80M -80M -91M -110M -83M -91M
ebitdaratio -13.143 -87.067 -2266.025 -575.101 -977.268 -2216.683 -304.969 -1136 -767.042
operatingIncome -80M -99M -95M -85M -80M -85M -112M -85M -91M
operatingIncomeRatio -13.143 -94.874 -2379.9 -607.935 -977.268 -2076.707 -309.944 -1163.014 -769.525
totalOtherIncomeExpensesNet -5M -35M -39M -149M -15M -21M -5M -23M -20M
incomeBeforeTax -86M -135M -134M -233M -96M -138M -117M -108M -111M
incomeBeforeTaxRatio -14.04 -128.543 -3353.25 -1679.525 -1165.634 -3371.049 -323.842 -1483.452 -942.042
incomeTaxExpense 0 0 -21 000 -40 000 -5M 21M 35M 34 000 -223 000
netIncome -86M -135M -134M -233M -96M -138M -151M -108M -111M
netIncomeRatio -14.04 -128.523 -3352.725 -1679.079 -1165.634 -3362.902 -419.894 -1483.918 -940.153
eps -0.14 -0.2 -0.2 -0.35 -0.19 -0.32 -0.35 -0.27 -0.28
epsdiluted -0.14 -0.2 -0.2 -0.35 -0.19 -0.32 -0.35 -0.27 -0.28
weightedAverageShsOut 696M 687M 673M 671M 498M 437M 428M 400M 400M
weightedAverageShsOutDil 698M 687M 673M 671M 498M 437M 428M 400M 400M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IBRX IBRX IBRX IBRX IBRX IBRX IBRX IBRX IBRX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-12 2024-08-12 2024-05-09 2024-03-19 2023-11-09 2023-08-08 2023-05-11 2023-03-01 2022-11-09
acceptedDate 2024-11-12 07:30:57 2024-08-12 08:03:23 2024-05-09 17:00:00 2024-03-19 16:31:53 2023-11-08 21:28:46 2023-08-08 16:15:53 2023-05-11 06:47:06 2023-03-01 17:18:49 2022-11-08 20:52:01
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 112M 130M 133M 265M 178M 44M 88M 105M 104M
shortTermInvestments 18M 88M 37M 1M 12M 2M 3M 3M 7M
cashAndShortTermInvestments 130M 218M 170M 266M 190M 46M 91M 107M 111M
netReceivables 4M 2M 2M 3M 2M 3M 1M 2M 6M
inventory 2M 2M 0 0 16M 13M 16M 26M 0
otherCurrentAssets 27M 21M 23M 24M 7M 5M 5M 5M 6M
totalCurrentAssets 163M 243M 196M 294M 215M 67M 113M 141M 143M
propertyPlantEquipmentNet 174M 176M 179M 183M 188M 194M 198M 189M 177M
goodwill 910 000 0 0 0 0 0 0 0 0
intangibleAssets 16M 16M 17M 17M 18M 19M 20M 20M 20M
goodwillAndIntangibleAssets 16M 16M 17M 17M 18M 19M 20M 20M 20M
longTermInvestments 0 7M 7M 8M 817 000 841 000 820 000 6M 0
taxAssets 0 0 -1 1 7M 7M -820 000 0 0
otherNonCurrentAssets 11M 3M 3M 2M 3M 4M 12M 7M 13M
totalNonCurrentAssets 201M 201M 205M 210M 217M 224M 230M 222M 210M
otherAssets 0 1 1 0 0 0 0 0 0
totalAssets 365M 444M 401M 504M 432M 291M 343M 362M 353M
accountPayables 10M 20M 14M 9M 20M 25M 34M 21M 20M
shortTermDebt 7M 6M 7M 7M 4M 524M 474M 435M 1M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 100 000 100 000 100 000 100 000 -519M 0 0 0
otherCurrentLiabilities 44M 36M 33M 42M 66M 582M 57M 45M 49M
totalCurrentLiabilities 61M 62M 54M 58M 90M 613M 565M 501M 71M
longTermDebt 625M 993M 851M 837M 713M 295M 292M 289M 711M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 423M 87M 187M 195M 40M 28M 18M 22M 690M
totalNonCurrentLiabilities 1 048M 1 080M 1 038M 1 032M 753M 323M 310M 311M 711M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 7M 43M 38M 40M 44M 51M 49M 51M 51M
totalLiabilities 1 109M 1 142M 1 092M 1 090M 843M 936M 875M 812M 782M
preferredStock 0 0 0 0 0 3M 0 0 0
commonStock 0 69 000 68 000 67 000 67 000 44 000 43 000 42 000 40 000
retainedEarnings -3 316M -3 230M -3 096M -2 962M -2 728M -2 633M -2 495M -2 378M -2 270M
accumulatedOtherComprehensiveIncomeLoss 0 -8000 -7000 10000 792 000 -40 000 -33 000 183 000 -190 000
othertotalStockholdersEquity 2 572M 2 532M 2 404M 2 375M 2 316M 1 988M 1 966M 1 931M 1 844M
totalStockholdersEquity -744M -698M -692M -587M -412M -642M -529M -447M -427M
totalEquity -744M -697M -691M -586M -411M -645M -532M -447M -427M
totalLiabilitiesAndStockholdersEquity 365M 444M 401M 504M 432M 291M 343M 362M 353M
minorityInterest 0 1M 1M 1M 1M -3M -3M -2M 0
totalLiabilitiesAndTotalEquity 365M 444M 401M 504M 432M 291M 343M 362M 353M
totalInvestments 18M 95M 44M 9M 12M 2M 3M 8M 7M
totalDebt 632M 999M 895M 884M 717M 819M 766M 724M 712M
netDebt 520M 869M 762M 618M 539M 776M 678M 619M 608M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IBRX IBRX IBRX IBRX IBRX IBRX IBRX IBRX IBRX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-12 2024-08-12 2024-05-09 2024-03-19 2023-11-09 2023-08-08 2023-05-11 2023-03-01 2022-11-09
acceptedDate 2024-11-12 07:30:57 2024-08-12 08:03:23 2024-05-09 17:00:00 2024-03-19 16:31:53 2023-11-08 21:28:46 2023-08-08 16:15:53 2023-05-11 06:47:06 2023-03-01 17:18:49 2022-11-08 20:52:01
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -86M -135M -134M -233M -96M -138M -117M -108M -111M
depreciationAndAmortization 4M 4M 5M 5M 5M 5M 5M 5M 5M
deferredIncomeTax 0 0 0 -25M -14M 10M 0 -4000 0
stockBasedCompensation 7M 10M 8M 13M 14M 11M 11M 9M 11M
changeInWorkingCapital -1M 5M -4M -26M -7M 9M 28M -7M 11M
accountsReceivables -4M 0 0 0 0 0 0 0 0
inventory -2M 0 0 0 0 0 0 0 0
accountsPayables -9M 5M 4M -3M -3M -2M 668 000 437 000 1M
otherWorkingCapital 14M 708 000 -8M -23M -4M 11M 27M -7M 10M
otherNonCashItems -23M 15M 31M 151M 10M 23M -11M 10M 4M
netCashProvidedByOperatingActivities -99M -100M -107M -115M -87M -80M -84M -91M -81M
investmentsInPropertyPlantAndEquipment -3M -724 000 -1M -8M -6M -9M -8M -19M -16M
acquisitionsNet -1 000 000 0 0 -10M 0 0 0 1 000 000 0
purchasesOfInvestments 0 -86M -48M -166 000 -10M -78 000 -158 000 -19 000 -86 000
salesMaturitiesOfInvestments 70M 35M 14M 10M 0 0 102 000 56 000 15M
otherInvestingActivites -747 000 0 -34M 10M -10M 0 0 -1 000 000 0
netCashUsedForInvestingActivites 65M -51M -36M 2M -16M -9M -8M -19M -1M
debtRepayment -22 000 -21 000 -21 000 -193M -19 000 -19 000 -19 000 -18 000 0
commonStockIssued -18M 4M 14M 9M 40M 14M 47M 60M 0
commonStockRepurchased 4M 0 -4M -2M -1M -60 000 0 0 0
dividendsPaid 0 0 0 0 0 -60 000 0 0 0
otherFinancingActivites 16M 145M -4M 384M 200M 30M 30M 50M 124M
netCashUsedProvidedByFinancingActivities 16M 149M 10M 201M 238M 43M 77M 110M 124M
effectOfForexChangesOnCash 27 000 12 000 -39 000 -27 000 -1000 -10000 -254 000 161 000 43 000
netChangeInCash -18M -3M -132M 87M 134M -45M -16M 480 000 42M
cashAtEndOfPeriod 112M 130M 133M 265M 178M 44M 89M 105M 104M
cashAtBeginningOfPeriod 130M 133M 265M 178M 44M 89M 105M 104M 62M
operatingCashFlow -99M -100M -107M -115M -87M -80M -84M -91M -81M
capitalExpenditure -3M -724 000 -1M -8M -6M -9M -8M -19M -16M
freeCashFlow -102M -101M -108M -123M -93M -88M -93M -110M -97M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-12 12:15 ET
ImmunityBio Reports Third-Quarter 2024 Financial Results
2024-10-24 13:00 ET
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
2024-10-21 13:00 ET
ImmunityBio to Participate in the Jefferies London Healthcare Conference
2024-09-09 12:30 ET
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer 
2024-08-12 12:46 ET
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
2024-08-06 13:00 ET
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
2024-06-20 13:00 ET
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
2024-06-07 13:13 ET
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
2024-05-17 13:00 ET
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
2024-05-17 13:00 ET
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
2024-05-07 12:00 ET
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
2024-05-02 20:04 ET
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
2024-04-30 12:00 ET
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
2024-04-25 04:03 ET
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
2024-04-23 01:56 ET
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-03-06 14:00 ET
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
2024-03-05 14:00 ET
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
2024-02-21 14:00 ET
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
2024-02-05 14:00 ET
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
2024-01-02 11:00 ET
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
2023-11-16 14:00 ET
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
2023-11-07 14:00 ET
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
2023-10-26 13:00 ET
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
2023-10-23 13:00 ET
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
2023-09-11 10:00 ET
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
2023-08-03 13:00 ET
ImmunityBio Names Enrique Diloné as Chief Technology Officer
2023-07-21 00:32 ET
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
2023-07-10 13:30 ET
Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients
2023-05-22 13:00 ET
ImmunityBio to Participate in the Jefferies Global Healthcare Conference
2023-04-25 13:00 ET
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
2023-04-25 03:28 ET
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
2023-02-16 14:00 ET
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU
2023-02-15 14:00 ET
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
2023-01-19 14:00 ET
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
2022-12-12 13:30 ET
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
2022-11-17 14:00 ET
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
2022-11-10 21:00 ET
NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer
2022-10-27 12:00 ET
ImmunityBio to Participate in the Jefferies London Healthcare Conference
2022-07-28 20:18 ET
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
2022-06-06 13:00 ET
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
2022-05-23 12:32 ET
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
2022-04-28 13:00 ET
ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-04-25 13:00 ET
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
2022-04-01 20:15 ET
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
2022-03-02 14:00 ET
Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio’s Scaled m-ceNK Clinical Program
2022-02-14 22:17 ET
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer
2022-02-01 00:16 ET
ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy
2022-01-18 23:00 ET
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
2022-01-04 14:00 ET
ImmunityBio Awarded Seminal Patent on Natural Killer Cells
2022-01-03 13:00 ET
AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE
2021-12-21 13:00 ET
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer
2021-12-20 14:00 ET
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
2021-11-18 14:00 ET
ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines
2021-11-12 13:00 ET
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
2021-11-08 13:00 ET
Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine
2021-11-04 13:00 ET
ImmunityBio to Present at the Jefferies London Healthcare Conference
2021-10-19 13:00 ET
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
2021-10-14 12:00 ET
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
2021-10-13 13:00 ET
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
2021-10-04 12:30 ET
National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
2021-09-13 12:30 ET
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
2021-09-07 12:30 ET
ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives
2021-09-01 13:00 ET
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
2021-08-16 13:00 ET
ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion
2021-08-12 20:06 ET
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
2021-07-29 12:00 ET
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
2021-07-27 13:00 ET
ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent
2021-07-14 13:00 ET
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
2021-06-28 13:00 ET
ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients
2021-06-15 11:00 ET
FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer
2021-06-10 13:00 ET
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
2021-05-25 13:00 ET
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
2021-05-24 13:00 ET
ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference
2021-05-20 13:00 ET
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021
2021-05-17 13:00 ET
FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors
2021-05-13 12:00 ET
CytRx Comments on Quarterly Results and Year-to-Date Progress
2021-05-04 13:00 ET
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients
2021-04-29 13:00 ET
ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs
2021-04-22 13:00 ET
ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications
2021-04-08 13:00 ET
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
2021-04-01 13:00 ET
ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors
2021-03-29 13:00 ET
ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer
2021-03-22 13:00 ET
ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors
2021-03-15 13:00 ET
ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations
2021-03-11 14:00 ET
ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses
2021-03-09 21:15 ET
ImmunityBio and NantKwest Complete Merger
2021-03-08 21:30 ET
Stockholders of NantKwest Approve Merger With ImmunityBio
2021-03-08 14:00 ET
ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.
2021-02-25 00:26 ET
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio
2021-02-24 14:00 ET
ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors
2021-02-23 13:00 ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CTB, PBCT, HMSY, NK, SPWH
2021-02-16 14:00 ET
ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate
2021-02-11 23:13 ET
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
2021-01-28 14:00 ET
ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer
2021-01-15 13:00 ET
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients
2021-01-13 23:01 ET
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
2021-01-06 14:00 ET
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
2020-12-22 13:00 ET
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
2020-12-21 11:05 ET
 ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
2020-12-21 11:05 ET
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
2020-12-11 02:48 ET
ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
2020-11-23 14:00 ET
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
2020-11-18 14:15 ET
NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference
2020-11-10 12:00 ET
ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
2020-11-09 14:00 ET
ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2
2020-10-26 20:15 ET
NantKwest Names Richard Adcock Chief Executive Officer
2020-10-21 21:06 ET
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2
2020-10-15 10:00 ET
FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity
2020-10-06 20:05 ET
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care
2020-09-21 13:00 ET
NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit
2020-09-10 13:00 ET
Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
2020-08-24 13:00 ET
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
2020-08-10 11:00 ET
Cord Blood Registry (CBR®) By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment
2020-08-03 12:30 ET
ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
2020-06-29 20:05 ET
NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-06-25 05:01 ET
NantKwest Announces Pricing of Public Offering of Common Stock
2020-06-24 20:15 ET
NantKwest Announces Proposed Public Offering of Common Stock
2020-06-10 13:00 ET
 NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
2020-05-27 16:00 ET
ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine 
2020-05-26 13:30 ET
NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
2020-05-18 12:30 ET
NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
2020-05-14 20:25 ET
NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
2020-04-29 20:15 ET
NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
2020-04-14 12:30 ET
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter
2020-03-19 12:00 ET
NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
2020-01-16 13:00 ET
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
2020-01-14 13:00 ET
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
2019-12-16 12:00 ET
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS
2019-12-02 21:05 ET
NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
2019-11-27 13:00 ET
NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors
2019-11-07 21:15 ET
NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019

SEC forms

Show financial reports only

SEC form 10
2025-05-12 10:46 ET
ImmunityBio published news for 2025 q1
SEC form 10
2025-05-12 00:00 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-05-12 00:00 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-05-12 00:00 ET
ImmunityBio reported for 2025 q1
SEC form 8
2025-05-05 11:15 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-05-05 11:15 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-04-15 00:00 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-04-15 00:00 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-04-08 11:45 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-04-08 11:45 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-04-08 11:45 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-04-08 11:45 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-04-08 11:45 ET
ImmunityBio published news for 2025 q1
SEC form 8
2025-03-19 12:14 ET
ImmunityBio published news for 2024 q4
SEC form 8
2025-03-19 12:14 ET
ImmunityBio published news for 2024 q4
SEC form 10
2025-03-03 07:47 ET
ImmunityBio published news for 2024 q4
SEC form 8
2025-03-03 07:42 ET
ImmunityBio published news for 2024 q4
SEC form 8
2025-03-03 07:42 ET
ImmunityBio reported for 2024 q4
SEC form 10
2025-03-03 00:00 ET
ImmunityBio published news for 2024 q4
SEC form 10
2024-11-12 07:30 ET
ImmunityBio reported for 2024 q3
SEC form 8
2024-11-12 07:25 ET
ImmunityBio published news for 2024 q3
SEC form 8
2024-11-12 07:25 ET
ImmunityBio reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
ImmunityBio reported for 2024 q3
SEC form 10
2024-08-12 08:03 ET
ImmunityBio reported for 2024 q2
SEC form 10
2024-08-12 00:00 ET
ImmunityBio reported for 2024 q2
SEC form 10
2024-05-09 17:00 ET
ImmunityBio published news for 2024 q1
SEC form 10
2024-05-09 00:00 ET
ImmunityBio published news for 2024 q1
SEC form 10
2024-03-19 16:31 ET
ImmunityBio published news for 2023 q4
SEC form 10
2024-03-19 00:00 ET
ImmunityBio published news for 2023 q4
SEC form 10
2023-11-09 00:00 ET
ImmunityBio reported for 2023 q3
SEC form 10
2023-11-08 21:28 ET
ImmunityBio reported for 2023 q3
SEC form 6
2023-08-15 16:15 ET
ImmunityBio published news for 2023 q2
SEC form 10
2023-08-08 16:15 ET
ImmunityBio reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
ImmunityBio reported for 2023 q2
SEC form 6
2023-07-21 06:04 ET
ImmunityBio published news for 2023 q2
SEC form 6
2023-07-20 16:07 ET
ImmunityBio published news for 2023 q2
SEC form 6
2023-06-14 17:15 ET
ImmunityBio published news for 2023 q1
SEC form 10
2023-05-11 06:47 ET
ImmunityBio reported for 2023 q1
SEC form 6
2023-05-11 06:45 ET
ImmunityBio published news for 2023 q1
SEC form 10
2023-05-11 00:00 ET
ImmunityBio reported for 2023 q1
SEC form 6
2023-03-31 16:29 ET
ImmunityBio published news for 2022 q4
SEC form 6
2023-03-20 08:31 ET
ImmunityBio published news for 2022 q4
SEC form 10
2023-03-01 17:18 ET
ImmunityBio reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
ImmunityBio reported for 2022 q4
SEC form 6
2023-02-15 09:20 ET
ImmunityBio published news for 2022 q4
SEC form 6
2023-02-14 17:25 ET
ImmunityBio published news for 2022 q4
SEC form 8
2023-02-14 00:00 ET
ImmunityBio published news for 2022 q4
SEC form 6
2023-02-13 08:02 ET
ImmunityBio published news for 2022 q4
SEC form 6
2022-12-12 09:07 ET
ImmunityBio published news for 2022 q3
SEC form 6
2022-12-05 10:51 ET
ImmunityBio published news for 2022 q3
SEC form 6
2022-11-15 08:42 ET
ImmunityBio published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
ImmunityBio reported for 2022 q3
SEC form 10
2022-11-08 20:52 ET
ImmunityBio reported for 2022 q3
SEC form 6
2022-09-02 16:15 ET
ImmunityBio published news for 2022 q2
SEC form 10
2022-08-08 16:45 ET
ImmunityBio reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
ImmunityBio reported for 2022 q2
SEC form 6
2022-06-15 21:26 ET
ImmunityBio published news for 2022 q1
SEC form 6
2022-06-15 21:24 ET
ImmunityBio published news for 2022 q1
SEC form 6
2022-06-15 21:20 ET
ImmunityBio published news for 2022 q1
SEC form 6
2022-06-15 21:19 ET
ImmunityBio published news for 2022 q1
SEC form 6
2022-06-15 21:16 ET
ImmunityBio published news for 2022 q1
SEC form 6
2022-06-14 16:59 ET
ImmunityBio published news for 2022 q1
SEC form 10
2022-05-10 16:08 ET
ImmunityBio reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
ImmunityBio reported for 2022 q1
SEC form 6
2022-04-29 16:11 ET
ImmunityBio published news for 2022 q1
SEC form 6
2022-03-25 21:05 ET
ImmunityBio published news for 2021 q4
SEC form 6
2022-03-25 17:23 ET
ImmunityBio published news for 2021 q4
SEC form 10
2022-03-01 17:03 ET
ImmunityBio published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
ImmunityBio published news for 2021 q4
SEC form 6
2022-02-15 09:00 ET
ImmunityBio published news for 2021 q4
SEC form 6
2022-01-12 08:35 ET
ImmunityBio published news for 2021 q4
SEC form 6
2022-01-10 19:46 ET
ImmunityBio published news for 2021 q4
SEC form 6
2021-12-29 21:27 ET
ImmunityBio published news for 2021 q3
SEC form 6
2021-12-20 09:07 ET
ImmunityBio published news for 2021 q3
SEC form 6
2021-11-12 17:07 ET
ImmunityBio published news for 2021 q3
SEC form 10
2021-11-12 16:38 ET
ImmunityBio published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
ImmunityBio published news for 2021 q3
SEC form 6
2021-09-27 08:46 ET
ImmunityBio published news for 2021 q2
SEC form 6
2021-09-13 08:37 ET
ImmunityBio published news for 2021 q2
SEC form 8
2021-09-13 00:00 ET
ImmunityBio published news for 2021 q2
SEC form 6
2021-08-13 16:16 ET
ImmunityBio published news for 2021 q2
SEC form 10
2021-08-12 16:29 ET
ImmunityBio published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
ImmunityBio published news for 2021 q2
SEC form 6
2021-06-15 07:11 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-06-11 17:18 ET
ImmunityBio published news for 2021 q1
SEC form 8
2021-06-11 00:00 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-06-04 08:30 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-05-28 16:08 ET
ImmunityBio published news for 2021 q1
SEC form 10
2021-05-14 16:06 ET
ImmunityBio published news for 2021 q1
SEC form 10
2021-05-14 00:00 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-05-03 06:06 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-04-29 16:31 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-04-22 16:06 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-04-01 18:27 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-04-01 09:15 ET
ImmunityBio published news for 2021 q1
SEC form 6
2021-03-17 17:24 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-03-11 21:50 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-03-11 21:49 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-03-11 21:48 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-03-11 21:47 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-03-09 21:58 ET
ImmunityBio published news for 2020 q4
SEC form 10
2021-03-04 16:11 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-02-25 17:15 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-02-24 16:59 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-02-10 16:38 ET
ImmunityBio published news for 2020 q4
SEC form 6
2021-01-13 09:17 ET
ImmunityBio published news for 2020 q4
SEC form 6
2020-12-22 06:07 ET
ImmunityBio published news for 2020 q3
SEC form 6
2020-12-21 07:23 ET
ImmunityBio published news for 2020 q3
SEC form 10
2020-11-09 16:06 ET
ImmunityBio published news for 2020 q3
SEC form 6
2020-10-29 16:19 ET
ImmunityBio published news for 2020 q3
SEC form 6
2020-10-26 17:05 ET
ImmunityBio published news for 2020 q3